Surrozen (SRZN) Shares Outstanding (2020 - 2026)
Surrozen (SRZN) posted quarterly Shares Outstanding (Entity) of $10949.0 for Q1 2026, up 201.79% year-over-year from $3628.0 in Q1 2025, and up 46.42% quarter-over-quarter from $7478.0 in Q4 2025.
Analysis
Surrozen (SRZN) Shares Outstanding (2020 - 2026) Analysis & Trends
Surrozen's Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $10949.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 201.79% year-over-year to $10949.0; the TTM figure through Mar 2026 stood at $10949.0 (up 201.79% YoY), while the FY2025 annual figure was $7478.0, up 154.96% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $10949.0, up from $7478.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $3.2 million in Q3 2024, with the low at $1998.0 in Q1 2023.
- The 5-year median for Shares Outstanding (Entity) is $3628.0 (2025), against an average of $622947.2.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) plunged 99.87% in 2022, then surged 87375.06% in 2023.
- Surrozen's Shares Outstanding (Entity) stood at $2315.0 in 2022, then retreated by 12.83% to $2018.0 in 2023, then soared by 45.34% to $2933.0 in 2024, then jumped by 154.96% to $7478.0 in 2025, then soared by 46.42% to $10949.0 in 2026.
- Business Quant data shows SRZN's Shares Outstanding (Entity) at $10949.0 in Q1 2026, $7478.0 in Q4 2025, and $8571.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Surrozen | 258.80 Mn | 258.80 Mn | - | 11.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.66 Mn |
| Mar 31, 2026 | 10.95 Mn |
| Dec 31, 2025 | 7.48 Mn |
| Sep 30, 2025 | 8.57 Mn |
| Jun 30, 2025 | 8.54 Mn |
| Mar 31, 2025 | 3.63 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 3.16 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Dec 31, 2023 | 2.02 Mn |
| Sep 30, 2023 | 2.03 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.33 Mn |
| Jun 30, 2022 | 2.33 Mn |
| Mar 31, 2022 | 2.32 Mn |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.83 Mn |